End-of-day quote
Other stock markets
|
||
- EUR | - |
04-08 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
04-03 | Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March | MT |
Sales 2024 * | 471B 3.01B 2.81B 4.11B | Sales 2025 * | 483B 3.09B 2.88B 4.22B | Capitalization | 1,407B 9.01B 8.4B 12.3B |
---|---|---|---|---|---|
Net income 2024 * | 66.51B 426M 397M 581M | Net income 2025 * | 72.93B 467M 435M 637M | EV / Sales 2024 * | 2.29 x |
Net cash position 2024 * | 330B 2.11B 1.97B 2.88B | Net cash position 2025 * | 361B 2.31B 2.15B 3.15B | EV / Sales 2025 * | 2.17 x |
P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
19.1
x | Employees | - |
Yield 2024 * |
2.21% | Yield 2025 * |
2.31% | Free-Float | 45.89% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | - | 86-03-31 | |
Masashi Miyamoto
PSD | President | 64 | 85-03-31 |
Chief Tech/Sci/R&D Officer | 62 | 10-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Oyamada
BRD | Director/Board Member | 68 | 21-02-28 |
Yoshihisa Suzuki
BRD | Director/Board Member | 68 | 22-02-28 |
Director/Board Member | 66 | 08-09-30 |
1st Jan change | Capi. | |
---|---|---|
+4.06% | 70.44B | |
-14.44% | 4.75B | |
+41.60% | 4.5B | |
+5.96% | 3.85B | |
+23.46% | 2.38B | |
-19.32% | 2.34B | |
-27.04% | 2.2B | |
+7.97% | 1.96B | |
-0.50% | 1.64B |